Latest & greatest articles for nebivolol

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on nebivolol or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on nebivolol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for nebivolol

1. Nebivolol

Nebivolol Top results for nebivolol - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for nebivolol The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

2018 Trip Latest and Greatest

2. Nebivolol

Nebivolol USE OF NEBIVOLOL IN PREGNANCY 0344 892 0909 USE OF NEBIVOLOL IN PREGNANCY (Date of issue: February 2016 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . Summary Nebivolol is a cardioselective (beta-1 selective) beta-adrenoceptor blocking drug (beta-blocker) licensed for the treatment (...) of hypertension and chronic heart failure. There are no studies of rates of specific pregnancy outcomes following gestational exposure to nebivolol. An evidence-based assessment of the potential risks of congenital malformation spontaneous abortion, stillbirth, intrauterine growth restriction (IUGR), preterm delivery and adverse neurodevelopmental effects following in utero exposure is therefore not possible and women should be made aware of this lack of data. Studies of beta-blockers as a class have

2014 UK Teratology Information Service

3. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. (PubMed)

Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. The fixed-dose combination of any two antihypertensive drugs from different drug classes is typically more effective in reducing blood pressure than a dose increase of component monotherapy. We assessed the efficacy and safety of a fixed-dose combination of a vasodilating β blocker (nebivolol) and an angiotensin II receptor blocker (valsartan) in adults with hypertension.We (...) did an 8-week, phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group trial at 401 US sites. Participants (age ≥18 years) with hypertension but with blood pressure less than 180/110 mm Hg were randomly assigned (2:2:2:2:2:2:2:1) by a 24-h interactive web response system in blocks of 15 to 4 weeks of double-blind treatment with nebivolol and valsartan fixed-dose combination (5 and 80 mg/day, 5 and 160 mg/day, or 10 and 160 mg/day), nebivolol (5 mg/day or 20 mg/day

2014 Lancet Controlled trial quality: predicted high

4. Nebivolol - Essential hypertension

Nebivolol - Essential hypertension Common Drug Review CDEC Meeting – June 19, 2013 Notice of CDEC Final Recommendation – July 18, 2013 Page 1 of 4 © 2013 CADTH CDEC FINAL RECOMMENDATION NEBIVOLOL (Bystolic – Forest Laboratories Canada Inc.) Indication: Mild to Moderate Essential Hypertension Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that nebivolol not be listed at the submitted price. Reasons for the Recommendation: 1. The evidence for nebivolol does not support (...) greater efficacy or safety than less costly alternative treatments for mild to moderate essential hypertension. 2. At the submitted price ($1.20 per day), nebivolol is more expensive than other beta- blockers reimbursed for the treatment of essential hypertension ($71 to $403 more per year). Of Note: Based on a review of the clinical evidence, the Committee felt that a reduced price would increase the likelihood of a recommendation to “list” or “list with clinical criteria and/or conditions

2013 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

5. Meta-Analysis of Carvedilol Versus Beta 1 Selective Beta-Blockers (Atenolol, Bisoprolol, Metoprolol, and Nebivolol) (PubMed)

Meta-Analysis of Carvedilol Versus Beta 1 Selective Beta-Blockers (Atenolol, Bisoprolol, Metoprolol, and Nebivolol) Because carvedilol is a unique vasodilating β blocker (BB) exerting antioxidant activity and pleiotropic effects, it was theorized that it may confer more potent beneficial effects on cardiovascular mortality and morbidity in acute myocardial infarction (AMI) and heart failure (HF) settings. A systematic review and meta-analysis was performed of randomized, controlled, direct (...) -comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF. Compared to β(1)-selective BBs used in HF (8 trials, n = 4,563), carvedilol significantly reduced all-cause mortality (risk ratio 0.85, 95% confidence interval 0.78 to 0.93, p = 0.0006). In 3 trials of patients with AMI (n = 644

2013 EvidenceUpdates

6. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (PubMed)

Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS In this pre-specified subanalysis of the SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure) trial, which examined the effects of nebivolol in elderly heart failure (HF) patients, we explored the effects of left ventricular ejection fraction (EF) on outcomes, including the subgroups (...) impaired EF (< or =35%) and preserved EF (>35%).Beta-blockers are established drugs in patients with HF and impaired EF, but their value in preserved EF is unclear.We studied 2,111 patients; 1,359 (64%) had impaired (< or =35%) EF (mean 28.7%) and 752 (36%) had preserved (>35%) EF (mean 49.2%). The effect of nebivolol was investigated in these 2 groups, and it was compared to explore the interaction of EF with outcome. Follow-up was 21 months; the primary end point was all-cause mortality

Full Text available with Trip Pro

2009 EvidenceUpdates Controlled trial quality: predicted high

7. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis

Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis Van Bortel L M, Fici F, Mascagni F CRD summary The authors concluded that nebivolol 5 mg may have benefits in hypertensive patients compared to existing antihypertensives and may have a role (...) in the first-line treatment of hypertension. Evidence appeared to support the authors’ conclusions, but the limited search and inadequate validity assessment made it difficult to comment on the strength of the evidence underpinning the authors’ conclusions. Authors' objectives To evaluate the efficacy and tolerability of nebivolol (a highly selective beta1-blocker) in patients with hypertension. Searching MEDLINE was searched to 2007 for studies published in full in English. Search terms were reported

2008 DARE.

8. Long-term cost-effectiveness analysis of nebivolol compared with standard care in elderly patients with heart failure: an individual patient-based simulation model

Long-term cost-effectiveness analysis of nebivolol compared with standard care in elderly patients with heart failure: an individual patient-based simulation model Long-term cost-effectiveness analysis of nebivolol compared with standard care in elderly patients with heart failure: an individual patient-based simulation model Long-term cost-effectiveness analysis of nebivolol compared with standard care in elderly patients with heart failure: an individual patient-based simulation model Yao G (...) , Freemantle N, Flather M, Tharmanathan P, Coats A, Poole-Wilson P A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of nebivolol in comparison with standard care for the treatment of chronic

2008 NHS Economic Evaluation Database.

9. Nebivolol in the management of essential hypertension: a review

Nebivolol in the management of essential hypertension: a review Nebivolol in the management of essential hypertension: a review Nebivolol in the management of essential hypertension: a review McNeely W, Goa K L Authors' objectives To evaluate the effectiveness of nebivolol, a beta-blocker, in patients with mild to moderate essential hypertension. Searching Medial literature published in any language since 1966 was identified using AdisBase (a proprietary database of Adis international, Auckland (...) , New Zealand), MEDLINE and EMBASE. AdisBase search terms were 'nebivolol' and 'hypertension'. MEDLINE and EMBASE search terms were 'nebivolol' and 'hypertension'. Searches were last updated 12 May 1988. Additional references were identified form the reference lists of published articles. Bibliographic information, including contributory unpublished data, was also requested from the company developing the drug. Study selection Study designs of evaluations included in the review Controlled trials

1999 DARE.